New myths about English - Volume 21, Issue

My first 39 myths about English were published in The Write Stuff in a series of articles between January 2006 and January 2008. The myths are mainly drawn from claims about English made by participants at my training events on the use of English…

Stijn Staples

Cate Talley

The data economy: A glossary - Volume 29, Issue

The data economy comes with its own terminologies and buzzwords (Table 1), stakeholders (Table 2), and activities (Table 3). This glossary aims to help readers navigate this data-driven environment.

Getting Your Foot in the Door - Volume 31, Issue

“Do your homework, knowledge is power!” my teachers used to say. Yes, we learn a lot during our education, respect the rules of the system, and we rely on that knowledge. However, once that stage is over, we are overwhelmed with possibilities and sta…

A guide to pre-approval regulatory documents - Volume 23, Issue

Diversity in clinical trials: It takes a village - Volume 32, Issue

Clinical trials are becoming more complex and the efforts to optimise drug development are rapidly evolving. This Q&A gives a short overview of the strategies Bristol Myers Squibb implements to incorporate diversity into the clinical trial…

Out on Our Own - Volume 27, Issue

One of the main reasons why the Freelance Business Group (and the whole of EMWA as well) is thriving and growing is because of the number of our members who volunteer to carry out our activities and help in implementing new initiatives. Becoming a…

Do you have what it takes to be a mentor or be mentored? - Volume 30, Issue

A skilled mentor can positively impact a mentee’s personal and professional development. A successful mentor-mentee relationship is contingent on mentor and mentee attributes, trust, and respect, and fit based on shared values and working style. To…

Challenges of paediatric drug development and impact of paediatric legislation - Volume 21, Issue

Medical writers are increasingly involved in designing and documenting overall plans in paediatric drug development, e.g. EU PIPs (Paediatric Investigation Plans) and individual components, e.g. protocols and study reports. It is essential to…